邁普醫學(301033.SZ):“可吸收再生氧化纖維素”止血產品是專門針對神經外科手術止血需求所開發的高性能止血產品
格隆匯5月11日丨有投資者在投資者互動平台向邁普醫學(301033.SZ)提問,“公司可吸收氧化纖維素和硬腦脊醫用膠國內的競爭公司是哪幾家?競品是什麼?國際的呢?”
邁普醫學回複稱,公司的“可吸收再生氧化纖維素”止血產品是專門針對神經外科手術止血需求所開發的高性能止血產品。硬腦膜醫用膠適用於開顱手術中,硬腦膜縫合部位的輔助封合,防止腦脊液滲漏。目前,公司是國內神經外科領域唯一同時擁有人工硬腦(脊)膜補片、顱頜面修補產品、可吸收再生氧化纖維素、硬腦膜醫用膠等植入醫療器械產品的企業,覆蓋開顱手術所需要的關鍵植入醫療器械。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.